Anti-obesity and Anti-aging Natural Products

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".

Deadline for manuscript submissions: 20 August 2024 | Viewed by 2145

Special Issue Editors


E-Mail Website
Guest Editor
Department of Medical and Surgical Sciences, University “Magna Græcia” of Catanzaro, 88100 Catanzaro, Italy
Interests: elderly; food; nutraceutical; extracts; nanoparticles; drug delivery; antioxidants; obesity; diabetes; cardiovascular diseases; metabolic disorders; myopathy; osteoporosis; cancer

E-Mail Website
Guest Editor
Laboratoy of Pharmaceutical Biology, IRC-FSH, Department of Health Sciences, University "Magna Græcia" of Catanzaro, Catanzaro, Italy
Interests: medicinal plants; extraction and isolation of compounds of natural origin; phytochemical analysis; biological activity
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Aging represents a progressive physiological senescence or a decline in biological functioning. Several cofactors can accelerate and promote this physiological phenomenon, including obesity, a condition expected to affect around one billion people by 2030.

In order to reduce medications and their related adverse effects, there is a growing interest in natural products that can mitigate or resolve pathologies as well as counteract the aging process. Indeed, different natural products might boost metabolism, suppress appetite, inhibit fat absorption, and help to reduce the signs of aging by combating free radicals, promoting skin health, and supporting cellular repair.

For this reason, we aim to develop a Special Issue for Pharmaceuticals that identifies “Anti-obesity and Anti-aging Natural Products”: those substances derived from plants, herbs, and other natural sources that are supposed to combat obesity or slow down physiological aging processes.

Dr. Rosario Mare
Dr. Vincenzo Musolino
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • anti-obesity
  • anti-aging
  • natural products
  • herbal remedies
  • antioxidants
  • weight management
  • aging prevention
  • phytochemicals
  • botanical extracts
  • metabolic health
  • healthy aging

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

18 pages, 2940 KiB  
Article
Neuroprotective Effects of Glycyrrhiza glabra Total Extract and Isolated Compounds
by Ali O. E. Eltahir, Sylvester I. Omoruyi, Tanya N. Augustine, Robert C. Luckay and Ahmed A. Hussein
Pharmaceuticals 2024, 17(7), 852; https://doi.org/10.3390/ph17070852 - 28 Jun 2024
Viewed by 408
Abstract
Glycyrrhiza glabra L. is a plant commonly utilized in herbal medicine and stands out as one of the more extensively researched medicinal plants globally. It has been documented with respect to several pharmacological activities, notably, neuroprotective effects, among others. However, the neuroprotective activity [...] Read more.
Glycyrrhiza glabra L. is a plant commonly utilized in herbal medicine and stands out as one of the more extensively researched medicinal plants globally. It has been documented with respect to several pharmacological activities, notably, neuroprotective effects, among others. However, the neuroprotective activity of pure phenolic compounds has not been reported yet. The chromatographic of a methanolic extract yielded twenty-two compounds, viz.: naringenin 4′-O-glucoside (1), 3′,4′,7-trihydroxyflavanone (butin) (2), liquiritin (3), liquiritin apioside (4), abyssinone (5), glabrol (6), isoliquiritin (7), neoisoliquiritin (8), isoliquiritin apioside (9), licuraside (10). 3’[O], 4’-(2,2-dimethylpyrano)-3,7-dihydroxyflavanone (11), glabrocoumarin (12), glabrene (13), isomedicarpin (14), 7-hydroxy-4′-methoxyflavone (formononetin) (15), ononin (16), glycyroside (17), (3S)-7,4′-dihydroxy-2′-methoxyisoflavan (18), glabridin (19), neoliquiritin (20), 3,11-dioxooleana-1,12-dien-29-oic acid (21), and 3-oxo-18β-glycyrrhetinic acid (22). The results of the neuroprotection evaluation showed that G. glabra total extract (TE) and compounds 1, 7, 11, 16, and 20 protected SH-SY5Y cells by inhibiting the depletion of ATP and elevated caspase 3/7 activities induced by MPP+. Indeed, this study reports for the first time the structure and activity of compound 11 and the neuroprotective activity of some phenolic constituents from G. glabra. Full article
(This article belongs to the Special Issue Anti-obesity and Anti-aging Natural Products)
Show Figures

Figure 1

Review

Jump to: Research

35 pages, 1938 KiB  
Review
White-to-Beige and Back: Adipocyte Conversion and Transcriptional Reprogramming
by Stanislav Boychenko, Vera S. Egorova, Andrew Brovin and Alexander D. Egorov
Pharmaceuticals 2024, 17(6), 790; https://doi.org/10.3390/ph17060790 - 16 Jun 2024
Viewed by 1231
Abstract
Obesity has become a pandemic, as currently more than half a billion people worldwide are obese. The etiology of obesity is multifactorial, and combines a contribution of hereditary and behavioral factors, such as nutritional inadequacy, along with the influences of environment and reduced [...] Read more.
Obesity has become a pandemic, as currently more than half a billion people worldwide are obese. The etiology of obesity is multifactorial, and combines a contribution of hereditary and behavioral factors, such as nutritional inadequacy, along with the influences of environment and reduced physical activity. Two types of adipose tissue widely known are white and brown. While white adipose tissue functions predominantly as a key energy storage, brown adipose tissue has a greater mass of mitochondria and expresses the uncoupling protein 1 (UCP1) gene, which allows thermogenesis and rapid catabolism. Even though white and brown adipocytes are of different origin, activation of the brown adipocyte differentiation program in white adipose tissue cells forces them to transdifferentiate into “beige” adipocytes, characterized by thermogenesis and intensive lipolysis. Nowadays, researchers in the field of small molecule medicinal chemistry and gene therapy are making efforts to develop new drugs that effectively overcome insulin resistance and counteract obesity. Here, we discuss various aspects of white-to-beige conversion, adipose tissue catabolic re-activation, and non-shivering thermogenesis. Full article
(This article belongs to the Special Issue Anti-obesity and Anti-aging Natural Products)
Show Figures

Figure 1

Back to TopTop